Shiga toxin-producing Escherichia coli O157 more frequently cause bloody diarrhea than do non-O157 strains.

NOTE. CI, confidence interval; OR, odds ratio. a O145, O111, O103, O26, and the group of the remaining STEC were not statistically significant. 3. Mobberley-Schuman PS, Connelly B, Weiss AA. Phagocytosis of Bordetella pertussis incubated with convalescent serum. J Infect Dis 2003; 187:1646–53. 4. Rodriguez ME, Hellwig SM, van der Pol WL, Hozbor D, Leusen J, van de Winkel JGJ. Fc receptor-mediated immunity against Bordetella pertussis. J Immunol 2001; 167:6545–51. 5. King A, Berbers G, Hoogerhout P, van Oirschot H, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 2001; 147:2885–95. 6. Olin P, Rasmussen F, Gustafson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and fivecomponent acellular pertussis vaccines compared with whole-cell pertussis vaccines. Lancet 1997; 350:1569–77. 7. Mills KH, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998; 66: 594–602. 8. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a twocomponent acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15:1606–12. 9. Mooi FR, van Loo I, King A. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001; 7(Suppl 3):526–8. 10. van Boven M, de-Melker HE, Schellekens JF, Kretzschmar M. Waning immunity and subclinical infection in an epidemic model: implications for pertussis in The Netherlands. Math Biosci 2000; 164:161–82.